CPT1A and metabolic dysfunction-associated steatohepatitis: In vitro experiments also confirmed that the inhibition of these signaling molecules could effectively reduce the tumor spheroid formation, indicating that the activation of the LPL/FABP4/CPT1 axis in the NASH stage may be beneficial to the viability of TICs in liver tissue.